IU Health Bloomington understands that clinical research is an important contributor to patient satisfaction and improved clinical outcomes. The hospital is committed to aggressively developing a robust research environment in order to better serve the surrounding community and improve access to care throughout the IU Health System.
Our commitment to developing and maintaining a collaborative research environment allows our physicians to explore a variety of treatment options and allows them to provide cutting-edge therapies to their patients. Below is a list of the clinical trials available for participation at IU Health Bloomington. Please contact the IU Health Bloomington research office 812.353.5494 for more information.
Amgen #20120110 PI-Benjamin Parsons, DO
Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients Neulasta
SCUSF-0806 PI-David Lee, MD
Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin)
PROMIS PI-Benjamin Parsons, DO
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score (PROMIS)
CALBG 70807 PI-David Lee, MD
The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.
HOG GU12-159 PI-Benjamin Parsons, DO
Phase 2 study evaluating OGX-427 in patients w/ metastatic castrate-resistant prostate cancer who have PSA
SWOG 1216 PI-Benjamin Parsons, DO
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
HOG MM12 PI-Benjamin Parsons, DO
A Phase 1/2, Multicenter, Single-arm, Nonrandomized, Open-label and Dose-escalation Study of Weekly Carfilzomib and Dexamethasone for Patients With Progressive Multiple Myeloma.
ECOG E1A11 PI-Jeff Allerton, MD
E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
DSC127-2012 PI-Gene DeVane, DPM
A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects with Diabetes Mellitus
The Indiana Biobank
A collection of a blood sample and personal health information for use in future research studies